Description  Claims  Drawing  Cited references 

WO2010099536A   [0002] 
WO2014144763A   [0004] 
WO9822149A   [0007] 
US5641870A   [0060] 
US5021236A   [0071] 
US4938948A   [0071] 
US4472509A   [0071] 
EP0239400A   [0125] 
US6180370B   [0125] 
US5827690A   [0125] 
US4444887A   [0128] 
US4716111A   [0128] 
WO9846645A   [0128] 
WO9860433A   [0128] 
WO9824893A   [0128]  [0129] 
WO9816664A   [0128] 
WO9634096A   [0128]  [0129] 
WO9633735A   [0128]  [0129] 
WO9110741A   [0128] 
WO9201047A   [0129] 
EP0598877A   [0129] 
US5413923A   [0129] 
US5625126A   [0129] 
US5633425A   [0129] 
US5569825A   [0129] 
US5661016A   [0129] 
US5545806A   [0129] 
US5814318A   [0129] 
US5886793A   [0129] 
US5916771A   [0129] 
US5939598A   [0129] 
US8502018B   [0129] 
US6218149B   [0146]  [0146] 
EP0359096B1   [0146] 
US20020028486A   [0146] 
WO03035835A   [0146] 
US20030115614A   [0146] 
US6472511B   [0146] 
US6602684B   [0147] 
US277370   [0147] 
US113929   [0147] 
WO0061739A1   [0147] 
WO01292246A1   [0147] 
WO02311140A1   [0147] 
WO0230954A1   [0147] 
WO00061739A   [0147] 
EA01229125   [0147] 
US20030115614   [0147] 
US5670356A   [0180] 
US5874304A   [0180] 

mAbs   [0001] 
PROT. ENGIN., DESIGN & SELECTION   [0003] 
Mol Cancer Ther .   [0005] 
PNAS   [0006] 
Br. J. Cancer   [0008] 
J. NUCL. MED.   [0009] 
BioTechnology   [0055] 
Proc. Nat. Acad. Sci. U.S.A   [0055] 
Gene   [0055] 
J. Immunol.   [0055] 
J. Immunol.   [0055] 
J. Mol. Biol.   [0055] 
Nature   [0060] 
Science   [0060] 
Proc. Natl. Acad. Sci. USA   [0060] 
Proc. Natl. Acad. Sci. USA   [0060]  [0092] 
Structure   [0060] 
Antibody Engineering   [0060] 
Protein Eng.   [0060] 
Molecular Cloning: A Laboratory Manual   [0076] 
Structure   [0092] 
TIB Tech.   [0102] 
Clin. Biochem.   [0102] 
BioTechniques   [0102] 
Immunology Today   [0102] 
Nucl. Acids Res.   [0102]  [0129] 
Immunology Today   [0102] 
Current Opinion in Biotechnology   [0102]  [0129] 
Proc. Natl. Acad. Sci. U.S.A.   [0102]  [0129] 
J. Mol. Biol.   [0110]  [0111] 
Methods in Enzymology   [0110]  [0111] 
Nucleic Acids Res.   [0110]  [0111] 
Bioinformatics: A Practical Guide to the Analysis of Genes and Proteins   [0110]  [0111] 
Bioinformatics Methods and Protocols (Methods in Molecular Biology   [0110]  [0111] 
Ann. Biol. Clin.   [0112] 
Biotechniques   [0112] 
J. Mol. Recognit.   [0112] 
Anal. Biochem.   [0112] 
J. Clin. Oncol.   [0118] 
British J. Cancer   [0120] 
J. Nucl. Med.   [0120] 
Mol. Cancer Ther.   [0120] 
Clin. Cancer Res.   [0120] 
Brit. J. Cancer   [0123] 
Nucl. Med. Biol.   [0123] 
Nature   [0125] 
Nature   [0125] 
Science   [0125] 
Proc. Nat. Acad. Sci. U.S.A.   [0125] 
Proc. Natl. Acad. Sci. U.S.A.   [0125] 
Monoclonal Antibodies and Cancer Therapy   [0128] 
J. Immunol   [0128] 
Int. Rev. Immunol.   [0129] 
Immunol. Today   [0129] 
Biotechnol   [0130] 
Nature   [0138] 
Nat. Biotechnol.   [0147] 
Biotechnol. Bioeng.   [0147] 
J. Biol. Chem.   [0147] 
J. Biol. Chem.   [0147] 
JMB   [0147] 
J. Immunol.   [0151] 
Science   [0151] 
Cancer Res.   [0152] 
Cancer Res.   [0172] 
Molecular Cloning, A Laboratory Manual   [0176] 
Current Protocols in Molecular Biology   [0176] 
J. Biol. Chem.   [0191] 
Remington's The Science and Practice of Pharmacy   [0205] 
Remington: The Science and Practice of Pharmacy   [0208] 
Mol. Cancer Ther.   [0241] 
British J. Cancer   [0241] 
Nucl. Med. Biol.   [0244] 
Mol. Cancer Ther.   [0244] 
J. Immunol. Meth.   [0244] 
A33 antigen displays persistent surface expression   [0249] 
Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids   [0249] 
Rapid and specific targeting of monoclonal antibody A33 to a colon cancer xenograft in nude mice   [0249] 
I-huA33 Antibody PET of Colorectal Cancer   [0249] 
Preclinical Evaluation of Multistep Targeting of Diasialoganglioside GD2 Using an IgG-scFv Bispecific Antibody with High Affinity for GD2 and DOTA Metal Complex   [0249] 
Evaluation of glycodendron and synthetically-modified dextran clearing agents for mult-step targeting of radioisotopes for molecular imaging and radio immunotherapy   [0249] 
Predicting Response to Radioimmunotherapy from the Tumor Microenvironment of Colorectal Carcinomas   [0249] 
Pharmacokinetics of pretargeted monoclonal antibody 2D12.5 and Y-Janus-2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecanetetraacetic acid (DOTA) in BALB/c mice with KHJJ mouse adenocarcinoma: a model for Y radio immunotherapy   [0249] 
The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily   [0249] 
Preparation and preclinical evaluation of humanised a33 immunoconjugates for radio immunotherapy   [0249] 
Immunometric assay by flow cytometry using mixtures of two particle types of different affinity   [0249] 
A modular IgG-scFv bispecific antibody topology   [0249] 
Engineering an antibody with picomolar affinity to DOTA chelates of multiple radionuclides for pretargeted radio immunotherapy and imaging   [0249] 
I-huA33 antibody uptake is driven by a33 antigen concentration in tissues from colorectal cancer patients imaged by immuno-pet   [0249] 
A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake   [0249] 
Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer   [0249] 
Phase I study of anticolon cancer humanized antibody A33   [0249]